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Abstract
Background: Obesity is associated with tumor aggressiveness and disease-specific mortality for more than 15
defined malignancies, including prostate cancer. Preclinical studies suggest that weight loss from caloric restriction
and increased physical activity may suppress hormonal, energy-sensing, and inflammatory factors that drive
neoplastic progression; however, exact mechanisms are yet to be determined, and experiments in humans are
limited.
Methods: We conducted a randomized controlled trial among 40 overweight or obese, newly-diagnosed prostate
cancer patients who elected prostatectomy to explore feasibility of a presurgical weight loss intervention that
promoted a weight loss of roughly one kg. week−1 via caloric restriction and physical activity, as well as to assess
effects on tumor biology and circulating biomarkers. Measures of feasibility (accrual, retention, adherence, and
safety) were primary endpoints. Exploratory aims were directed at the intervention’s effect on tumor proliferation
(Ki-67) and other tumor markers (activated caspase-3, insulin and androgen receptors, VEGF, TNFβ, NFκB, and
4E-BP1), circulating biomarkers (PSA, insulin, glucose, VEGF, TNFβ, leptin, SHBG, and testosterone), lymphocytic
gene expression of corresponding factors and cellular bioenergetics in neutrophils, and effects on the gut
microbiome. Consenting patients were randomized in a 1:1 ratio to either: 1) weight loss via a healthful,
guidelines-based diet and exercise regimen; or 2) a wait-list control. While biological testing is currently
ongoing, this paper details our methods and feasibility outcomes.
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Results: The accrual target was met after screening 101 cases (enrollment rate: 39.6 %). Other outcomes
included a retention rate of 85 %, excellent adherence (95 %), and no serious reported adverse events. No
significant differences by age, race, or weight status were noted between enrollees vs. non-enrollees. The most
common reasons for non-participation were “too busy” (30 %), medical exclusions (21 %), and “distance” (16 %).
Conclusions: Presurgical trials offer a means to study the impact of diet and exercise interventions directly on
tumor tissue, and other host factors that are feasible and safe, though modifications are needed to conduct
trials within an abbreviated period of time and via distance medicine-based approaches. Pre-surgical trials are
critical to elucidate the impact of lifestyle interventions on specific mechanisms that mediate carcinogenesis
and which can be used subsequently as therapeutic targets.
Trial registration: NCT01886677
Keywords: Prostatic neoplasms, Diet, Physical activity, Exercise, Weight loss, Obesity, Intervention, PresurgicalBackground
Obesity is increasingly recognized as a risk factor for
cancer [1]. Currently, there is consensus that obesity
serves as a risk factor for eight different malignancies,
i.e., endometrial, colorectal, renal, esophageal, breast
(post-menopausal), thyroid, gall bladder, and pancreas
[2–4]. Moreover, obesity also serves as a poor prognostic
indicator for several other cancers – at least 15 in total
[5]. In prostate cancer, obesity is not associated with the
overall risk for disease, but it does place men at in-
creased risk for more aggressive cancer and disease-
specific mortality [6]. A recent multinational study in-
volving 10,106 prostate cancer cases from eight cohorts
with an average follow-up of 8.2 years found that
each 5 unit increase in prediagnostic body mass index
(BMI: kg/m2) was associated with an 8 % increase in
mortality (p-trend = 0.01) [7]. Weight gain after diag-
nosis and primary treatment was examined in an earl-
ier study among 26,479 prostate cancer patients; here,
each 5 unit increase in BMI was associated with 21 %
increased risk of biochemical recurrence (Relative Risk:
1.21, 95 % Confidence Interval: 1.11-1.31 P < 0.01) [8].
Despite strong observational evidence that a higher
BMI is associated with more aggressive and progressive
cancer, major gaps exist in our understanding of that re-
lationship with key research questions being: Are weight
loss interventions feasible in populations with cancer?
Does intentional weight loss result in improved cancer
control? What are the mechanisms by which negative
energy balance affects tumor biology and the host envir-
onment? Are the effects of caloric restriction and in-
creased energy expenditure through physical activity
similar or do they differ?
To date, there have been roughly 20 weight loss trials
among various oncology patient populations that have
been completed or are currently in the field that address
some of these questions. Most of these trials have been
conducted in breast cancer survivors and are modest insize; results show feasibility, safety, and a significant im-
pact on reducing adiposity and improving health-related
quality of life - largely focusing on physical functioning
and fitness [9]. In addition, many have assessed the im-
pact of weight loss on circulating biomarkers, such as in-
sulin and related entities (insulin-like growth factors and
binding proteins), adipokines, inflammatory markers, sex
steroid hormones, and related binding proteins. Findings
have been compiled in a review by Reeves et al. [9] and
show significant reductions in insulin in 2-of-6 studies
[10–15], and leptin in 3-of-3 studies [10, 14, 15]; how-
ever, other results are inconclusive largely due to inad-
equate statistical power. As of yet, no studies have
been completed that assess the impact of intentional
weight loss on recurrence or cancer-specific mortality,
though there are currently two European trials in the
field with this goal, i.e., the Simultaneous Study of
Docetaxel-Gemcitabine Combination adjuvant treat-
ment, and Extended Bisphosphonate and Surveillance
(SUCCESS-C) and the Diet and Androgens (DIANA-5)
trials [16, 17]. In prostate cancer, there have been only
three reported weight loss studies. The largest of these,
the RENEW trial (Reach Out to ENhancE Wellness in
Older Cancer Survivors) enrolled 261 prostate cancer
survivors within a study cohort that also included 380
other survivors of breast and colorectal cancer [18].
In this study, significant reductions in body weight
occurred and were associated with improvements in
physical functioning (the primary endpoint of the
trial). The two other randomized trials have been
modest in size with sample sizes of 8 and 19 [19, 20],
and also showed successful weight loss. In the trial by
Wright et al. [20] pre-post changes in serum insulin-
like growth factor binding protein (IGFBP)-3 were ob-
served between the control (−6.9 %) and intervention
groups (+2.8 %); though no differences were observed
in insulin, c-peptide, IGF-1 and adiponectin – again,
likely due to inadequate power. Despite the fact that
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presurgical setting, neither investigated the impact of
caloric restriction on tumor tissue.
The ability to ascertain the impact of interventions
directly on tumor tissue is considered a particular
strength of presurgical trials, and it is reasoned that by
monitoring intervention effects on Ki-67 proliferation
rates (a well-accepted tumor marker used for pharmaco-
logic studies and also one that has shown to be sensitive
to changes in diet and nutritional status) [21–23], the ef-
ficacy of an intervention could be assessed in a much
shorter period of time and with much smaller numbers
of participants; moreover, the biological mechanisms
through which the intervention exerts its therapeutic po-
tential could be ascertained directly. Originally proposed
as a resourceful way of testing chemopreventive agents,
Kelloff and colleagues proposed the use of presurgical
models over a wide range of cancers in a hallmark paper
published over two decades ago [24]. Since this time,
they have been used for the evaluation of therapeutic
agents [22, 25–28], but have been used far less fre-
quently to assess the impact of complementary therapies
that encompass diet and exercise with the expressed in-
tent of assessing the impact of the intervention on the
tumor. While the biological effects of lifestyle interven-
tions are believed to be far less potent than pharmaco-
logical agents, a phase II RCT conducted among 161
patients scheduled for prostatectomy found significantly
lower Ki-67 proliferation indexes in men randomized to
receive a 3-week regimen of 30 g/day of ground flaxseed
vs. those who did not receive it [21, 29]. Thus, this trial
serves as proof of concept that presurgical trials are in-
deed viable and valuable for testing lifestyle interven-
tions. However, their use has not been evaluated in
studies of energy balance that are aimed at assessing the
impact of caloric restriction or increased physical activity
on tumor tissue.
The purpose of this paper is to describe a pioneering
NIH-funded (R21 CA161263) RCT that utilizes a pre-
surgical model to explore the feasibility and effects of a
diet and exercise weight loss intervention on tumor pro-
liferation rates (Ki-67), as well as other outcomes in men
with newly-diagnosed prostate cancer. Herein, we de-
scribe the study design, research protocol, and the ne-
cessary adjustments made in order to conduct the
presurgical weight loss trial in men who elected prosta-




This two-armed (experimental arm: assigned immedi-
ately to a healthful energy-restricted diet + exercise inter-
vention to promote a mean weight loss of 2 pounds/week vs. wait-list control arm: assigned to receive the
intervention post-surgery) randomized controlled trial
(RCT) among 40 overweight or obese men newly-
diagnosed with prostate cancer was designed as a feasi-
bility study to explore whether weight loss during the
presurgical period was feasible and associated with fa-
vorable changes in tumor biology and the host environ-
ment. While the basic structure of the trial is almost
identical to that of the original NIH application, some
modifications were necessary to overcome barriers and
to implement the trial in a real-world setting; these
modifications are indicated in the subsequent para-
graphs. This protocol and all amendments were ap-
proved by the Institutional Review Board of the
University of Alabama at Birmingham (F11051002), in
compliance with the Helsinki Declaration, and registered
and reported according to Consolidated Standards of
Reporting Trials guidelines (NCT01886677). Fig. 1 pro-
vides an illustration of the study schema, and specific
aims are listed below (note that both the feasibility and
exploratory aims were fully established at the time of
grant submission and remained unaltered):
Feasibility aims
To determine the feasibility of the trial against common
process and safety benchmarks, i.e., accrual (completion
of targeted enrollment [n = 40] within two years) and
retention (≥80 %) in the overall sample, adherence
(completion ≥70 % of contact sessions), and safety
(absence of serious, life-threatening adverse events) in
the experimental intervention arm.
To quantify (mean change scores and variance) and
compare differences in body weight over the study
period between the experimental vs. the wait-list
control arms.
Exploratory aims
To obtain means and precision estimates and explore
pre-post between-arm differences on the following:
1) other adiposity measures (waist circumference
[WC], and % body fat); 2) energy intake and physical
activity (minutes/week and metabolic equivalents
[METs]); 3) serum markers and lymphocytic gene
expression related to insulin, leptin, testosterone, sex
hormone binding globulin (SHBG), Tumor Necrosis
Factor (TNF)-β, Vascular Endothelial Growth Factor
(VEGF), phosphatidylinositol 3 kinase (PI3K), and
Phosphatase and tensin homolog (PTEN) and prostate
specific antigen (PSA), and 4) functional and health-
related outcomes, e.g., V02submax and quality of life
(QoL).
To obtain means and precision estimates and explore
between-arm differences with regard to select clinical
outcomes (margin positivity, surgical complications,
operating time, and length of hospital stay) and also the
1. Initial contact and screening: Obtain data for eligibility and on age,  
race/ethnicity, mileage from their home to the study site, and whether their 
MD mentioned the study.
2. Pre-baseline assessment: Review informed consent; obtain verbal consent.  
Collect in-home measures: 3-day heart rate monitor, saliva and fecal  
samples, two 24-hour dietary recalls and questionnaires.
1a. Track ineligible or disinterested cases with 
demographic factors.
3. Baseline assessment: Review informed consent; obtain written consent.
Collect heart rate monitor, saliva and fecal samples, completed 
questionnaires. Obtain fasting blood draw, DXA and VO2submax.                    
Participants randomized to study arms at completion of testing.
Upon doctor’s release, wait-listed 
participants receive dietary 
instruction and physical activity 
content provided to the
Experimental Arm.
4a. Experimental Arm                                            
(Pre-surgical weight loss)
Dietitian counseling session to correct nutrient 
deficiencies and improve overall dietary 
composition and reduce calorie intake by 500-
1000 kcal/d - Twice weekly contact.
Daily physical activity plan provided by 
exercise physiologists to increase energy 
expenditure - Twice weekly contact.
4b. Wait-list Control Arm           
(Post-surgical weight loss)
Dietitian counseling session to correct 
nutrient deficiencies and improve 
overall dietary composition – weekly 
contact.
5. Pre-follow-up assessment: Collect in-home 
measures: 3-day heart rate monitor, saliva and fecal 
samples, two 24-hour dietary recalls and 
questionnaires.
6. Follow-up assessment Collect heart rate monitor, 
saliva and fecal samples, completed questionnaires. 
Obtain fasting blood draw, DXA and VO2submax.
Prostatectomy and collection of surgical pathology  
operating room and in-patient reports.  Secure 
paraffin-embedded tissue blocks.  
Fig. 1 Study schema
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(apoptosis), VEGF, androgen and insulin receptors
(AR and IR), PTEN, nuclear factor kappa-light-
chain-enhancer of activated B cells (NFκB), and
serine/threonine kinase (AKT).
To conduct correlative science exploration to assess
associations between 1) measures of adiposity and energy
intake and expenditure with biomarkers in the sera,
lymphocytes, and prostate tissue; 2) Ki-67 with other
markers within the tumor; and 3) levels of circulating
biomarkers compared with those in the tumor.
Additional aims
Two collaborative studies were added onto the
original NIH-funded investigation, and were supportedby institutional funding. The first is aimed at evaluating
of the effect of the weight loss intervention on the
mitochondria. This study, led by BC, is exploring
the impact of negative energy balance on cellular
bioenergetics and the respiratory burst in neutrophils
and monocytes, and also is exploring associations
between mitochondrial bioenergetic profiles and potential
mediators and biomarkers of prostate cancer progression,
such as rates of proliferation and apoptosis in the
tumor tissue and serum PSA. The second is aimed
at exploring the potential effects of the weight loss
intervention and any specific effects of caloric restriction
or increased physical activity on the gut microbiome
(CDM and TP).
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Prostate cancer patients were recruited from the urology
clinics at the University of Alabama at Birmingham
(UAB) and also the Urology Centers of Alabama. In
most cases, patients were initially contacted by tele-
phone, the study was explained and interest in the study
was elicited, along with data on race/ethnicity, age, and
distance from the study site. Patients who were not in-
terested were thanked for their time and then asked to
volunteer their reasons for disinterest; this information
was de-identified and recorded. Patients who expressed
an interest were then screened for eligibility using the
eligibility criteria listed in Table 1. Ineligible patients’ data
also were de-identified and recorded in the database.
Written consent from men who were eligible and in-
terested in participating was obtained using two different
procedures depending on the convenience of the patient
and the distance that they resided from the study site.
For the first option, consent was obtained during a pre-
baseline appointment at which a 24-h hour dietary recall
was conducted and men were provided with a pro-
grammed heart rate monitor (to collect 3 days of
physical activity data), fecal and saliva specimen home
collection containers, and questionnaires to complete on
sociodemographic factors, comorbidity, and QoL. For
the second option, men were express mailed the consent
form and all of the study materials mentioned previ-
ously, and a 24-h dietary recall was conducted over the
telephone after obtaining verbal consent; written consent
was then obtained at the baseline assessment.
Baseline assessments were scheduled at the convenience
of the patient and to accommodate a 12-h fast. Vital signs
were taken and any participants exhibiting uncontrolled
Stage III hypertension (>99 diastolic or >159 systolic
at rest) or cardiac abnormality were cleared by their
urologist prior to randomization [30]; one patient re-
quired clearance and would have been omitted from
the study had they not been cleared, since there haveTable 1 Inclusion and exclusion criteria
Inclusion criteria Exc
• Adult men (age 19+) with pathologically confirmed prostate cancer
who elected prostatectomy as their primary initial treatment.
• Scheduled for prostatectomy at one of the participating study sites.
• Potential lag-time between baseline (which had to be scheduled at
least 2 weeks from prostatic biopsy) and follow-up appointments of
at least 23 days a.
















a This criteria was changed from that of the original study (i.e., 10 weeks), because
this criteria to correspond to that of our previous RCT in which we found significant ef
the criteria, the mean length of time that participants were on study was 7 weeks21,29been serious cardiovascular events in previous exer-
cise studies among prostate cancer patients) [31]. At
both this visit and at follow-up (scheduled to accom-
modate a 12-h fast and within 3-days of prostatectomy)
testing was performed to assess anthropometrics, body
composition via dual energy x-ray absorptiometry (DXA),
fitness using VO2submax, and to collect blood (see section
on Measures/Measurement Points for detail). To help de-
fray costs associated with study participation and reduce
potential barriers to accrual, men were offered a monetary
incentive of $15 for each clinic assessment they com-
pleted, as well as $15/week to participate in clinic-based
physical activity sessions.
Randomization
After all baseline data and biospecimens were collected,
men were randomized stratified on race (African
American vs. others) and baseline BMI (25–29.9 vs. 30+)
to assure an even balance amongst study arms regarding
both factors which have been found previously to
influence disease progression or intervention adherence
[32, 33]. Men were assigned to one of two study arms:
(1) the Experimental Arm that received the weight loss
regimen immediately; or 2) the Wait-List Control Arm
that was offered the weight loss regimen after comple-
tion of the study period. The randomization sequence
and group allocation were generated by the biostatisti-
cian (RAD) using a computer-generated random number
sequence (PROC PLAN SAS® Ver. 9.4). Sealed envelopes
with study assignments were created and numbered; en-
velopes within each strata were opened in sequence and
assignments were verified against the original sequence
patterns.
Interventions
Experimental arm (immediate weight loss regimen)
Participants in this arm received counseling from a
registered dietitian (WDW, MA) on a healthy,lusion criteria
revious hormonal or neo-adjuvant chemotherapy.
nother active malignancy (exception non-melanoma skin cancer) in
dition to prostate cancer.
urrent health or medical condition that affects weight status,
g., untreated hyper- or hypo-thyroidism, etc.
e-existing medical condition that precludes adherence to unsupervised
ercise, e.g., severe orthopedic conditions, scheduled for a hip or knee
placement, boney metastases, paralysis, dementia, untreated stage
hypertension, or unstable angina, heart attack, congestive heart failure
r conditions that dictated hospitalization or oxygen within 6-months.
nable to read or speak English• Unwillingness to be randomized to either
e immediate weight loss intervention or the wait-listed control arms.
rolled in a formal weight loss program.
potential recruits were unwilling to delay their surgery; therefore, we modified
fects with a 3-week dietary regimen. It should be noted despite this reduction in
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Reference Intakes as well as food choice patterns
consistent with guidelines of the American Cancer
Society (ACS) and the World Cancer Research Fund –
American Institute of Cancer Research [34, 35]. The
Mifflin-St. Jeor equation with an assumption of seden-
tary behavior [(10 × body weight in kg) + (6.25 × height
in cm) – (5 × age) × 1.2], [36] was used to obtain energy
needs; subtraction of 1000 kcal/day was then used to
promote an average weight loss of two pounds/week
[36]. Participants were provided with references and
instructed to count their calories or use the “Choose
Your Foods” American Diabetes and Dietetic Association
exchange list system [37]. Food group distribution was
customized to suit patients’ needs and preferences; di-
etitians consulted 24-h dietary recalls to alert partici-
pants of suboptimal nutrient intakes in an effort to
correct any nutritional inadequacies through food
sources. Participants were instructed to count their
calories each day, as well as their minutes of exercise.
“The Calorie King: Calorie, Fat and Carbohydrate
Counter” (Family Health Publications, Costa Mesa, CA)
was provided along with a pocket-size log book. Partici-
pants were instructed to weigh themselves daily and pro-
vided with a scale if they did not have one [38]. Dietitian
follow-up occurred twice weekly with counseling either
provided face-to-face, via the telephone or through
email. In each session, dietary intakes were reviewed,
reinforcement provided, and challenges of the upcom-
ing week were discussed in an effort to problem solve
and arrive at potential strategies. The overarching
theoretical framework for this intervention was pro-
vided by Social Cognitive Theory which emphasizes
the importance of self-efficacy, skills development, and
self-monitoring in producing behavior change [39].
In addition, exercise physiologists also provided coun-
seling on regimens that ultimately would afford up to an
additional 250 to 500 kcal (kcal)/day deficit primarily
through aerobic exercise. As per the American College
of Sports Medicine (ACSM) guidelines, each training
session included not only the work-out, but also a 5-min
warm-up and cool down of slow walking and stretching
[40]. An incremental approach for the workout was
employed with ramping of intensity and volume from 60
to 80 % of maximum heart rate (MHR) as tolerance per-
mitted. Participants were encouraged to exercise at UAB
twice weekly under supervision where they trained on
ergometers and treadmills, and 5 times/week at home;
they were provided with heart rate monitors and instruc-
tion for use during these sessions to enhance and moni-
tor adherence. Trainers employed similar scheduling and
approaches to that of the dietitians and downloaded
heart rate monitors regularly. Given that some partici-
pants resided hundreds of miles from the study site,on-site training was not possible and necessitated a
regimen that relied exclusively on regular telephone
counseling and/or email exchanges and routinely
scheduled downloads of heart rate monitor data. Add-
itional coaching was provided during each contact
with the participant, regardless of whether the contact
was made by the dietitian or the exercise trainer,
since we sought to use every opportunity to reinforce
the intervention. The concession to deliver the weight
loss regimen through a distance-medicine approach
was made when we discovered that most patients
who elected to receive their prostatectomies at the
two study sites came from a broad catchment area
that included Alabama, Arkansas, Florida, Georgia, and
Mississippi.
Wait-listed control arm (delayed weight loss regimen)
As in the experimental arm, these participants were ap-
prised of suboptimal nutrient intakes that were apparent
from 24-h recalls and counseled by dietitians on food
sources to correct any nutritional inadequacies with
follow-up on a weekly basis. They also were offered the
weight loss regimen with up to six weeks of follow-up
once they had recovered from their surgery.
Safety
Study participants were monitored at least weekly over
the course of the study period, to discern adverse events.
We were especially interested in any serious or life-
threatening event (defined as a physical or cardiac event
which resulted in overnight hospitalization) that was at-
tributable to the intervention; however, none occurred.
Measures/Measurement points
A logic model of the study outcomes and their inter-
relationships is provided in Fig. 2. With the exception of
the collection of tumor tissue from diagnostic biopsies
and prostatectomy, study measures were performed at
baseline and follow-up (which occurred within three
days prior to surgical treatment). Detail on each of these
measures follows:
Anthropometric measures
All anthropometric measures were conducted in accord-
ance with procedures detailed in the Anthropometric
Standardization Reference Manual [41]. Height was
measured at baseline only using fixed stadiometer and to
the nearest 0.1 cm (without shoes). Weight was mea-
sured on a calibrated platform scale to the nearest 0.1 kg
(without shoes and in light clothing with pockets emp-
tied). BMI was calculated using the following formula:
kg/m2. WC was measured to the nearest 0.1 cm with a




























( blood loss, operating time, hospital stay,
from operating room reports and  the
medical record)
Change in Serum Biomarkers
insulin, glucose, Homeostasis Model Assessment
[HOMA], TNFβ, VEGF, leptin, total & free
testosterone, and SHBG
Change in Lymphocytic Gene Expression
Downregulation of receptors for insulin (INSR),
leptin(LEPR), androgen(AR); VEGF (VEGFR) &
TNF(FAS), kinases (PI3K & MAPK); PTEN;













Fig. 2 Logic model
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Total body fat mass and lean mass were measured by
DXA using a regularly calibrated Lunar Prodigy densi-
tometer (GE-Lunar Corporation, Madison, WI, software
version 12.3). Participants were required to wear light
clothing, remove all metal objects from their body, and
lie supine with arms at their sides while undergoing a
total body scan.
Cardiorespiratory fitness
Heart rate, oxygen consumption, ventilation, perceived
exertion, and the respiratory exchange ratio were moni-
tored during VO2submax assessments. Measurements
were begun with the participant seated for 5 min. The
treadmill testing used increasing intensity in four minute
intervals, i.e., it began at 2 miles per hour (MPH) at a
0 % incline, then 2 MPH at 4 % incline, 3 MPH at 4 %
incline, 4 MPH at 4 % incline, and finally 4 MPH at 8 %
incline (which few participants achieved), to a goal of
80 % of MHR, as defined by ACSM criteria [40]. Upon
completion of each interval, the above measures were
recorded and testing was terminated once 80 % MHR
was achieved. Total time on the treadmill was then
recorded.
Patient reported data and outcomes
At baseline, patients were asked to report all of the pre-
scribed and over-the-counter medications (including
dietary supplements) that they took; this list wasreviewed at the follow-up appointment and changes
were noted. At both time points self-administered
questionnaires assessed comorbidity, and QoL using the
Older Americans Resources and Services (OARS)
Comorbidity Index [42], and the RAND-36 and Prostate
Cancer Index [43, 44], respectively. Given the need to
collect data within a circumscribed time period, the 7-
day Physical Activity Recall was modified to a 3-day col-
lection period and administered by trained personnel at
each time point [45]. Self-reported physical activity data
were further supported by the collection of objective
heart rate monitor data using the Polar RS400 (Polar
Electro, Inc., Lake Success, NY) for each 3-day collection
period. Two-day dietary recalls were conducted by regis-
tered dietitians with random recalls of one weekday and
one weekend day carefully timed at baseline and follow-
up to invoke standardization [46]. The NCI-developed
ASA24 was used to analyze nutrient composition and
provides output on mean intakes of 64 food-related
components from the USDA Nutrient Database for
Dietary Studies and 31 food groups from the USDA
MyPyramid Equivalents Database [47]. In this project
the key data identified from this program were kilocalo-
ries, macronutrients, and nutrient density.
Circulating biomarkers
Blood (29.7 ml) was collected by venipuncture and sepa-
rated into sera, plasma, neutrophils, leukocytes, DNA
and RNA (dispersed in 0.5 ml of RNAlater®). The
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studies on cellular bioenergetics and respiratory burst as
previously described in papers by Chacko and colleagues
[48, 49] All other samples were stored at −80 °C (except
the sample in the RNAlater which was stored at −20 C).
All sera will be batch analyzed in duplicate. The follow-
ing biomarkers will be assayed using immunofluores-
cence (TOSOH AIA-II analyzer, TOSOH Corporation,
South San Francisco, CA): insulin; total testosterone;
SHBG; and PSA. Cytokines (TNFβ and VEGF), will be
run on a MSD imager (Meso Scale Diagnostics, Rockville,
MD). Radioimmunoassay will performed according to
manufacturer’s directions (Millipore RIA, Billerica, MA)
to ascertain leptin. Glucose will be assessed using a glu-
cose oxidase reagent as per Stanbio Sirrus (Stanbio Labs,
Boerne, TX).
In tandem with these biomarkers, we also will explore
gene expression of receptors for insulin (INSR), leptin
(LEPR), and androgen (AR), as well as for VEGF
(VEGFR) and TNF (FAS). We also will investigate gene
expression with regard to PTEN, specific kinases
(PI3K & MAPK), transcription factors (STAT), and regula-
tion of apoptosis (BCL2). The total RNA will be extracted
from the samples using a Trizol reagent (Invitrogen,
Carlsbad, CA) and RNeasy Mini Kit (QIAGEN, Valencia,
CA) according to the manufacturer’s instructions. The
concentration and purity of total RNA will be determined
by 2100 Bioanalyzer (Agilent Technologies, Santa Clara,
CA). cDNA will be synthesized from 1 μg RNA using
High Capacity cDNA Reverse Transcription Kits (life
technologies, Grand Island, NY) according to the manu-
facturer’s instructions. cDNA will then be amplified by
real-time PCR using TaqMan Universal Master Mix II (life
technologies) with a CFX Connect Real-Time PCR
Detection System (Bio-Rad, Hercules, CA). Primers
will be obtained from TaqMan Gene Expression Assay
(life technologies, Grand Island, NY). The expression
levels of genes will be normalized to the expression
level of the 18 s rRNA in each sample. For mRNA
analysis, the calculations for determining the relative
level of gene expression will be made using the cycle
threshold method.
Tumor biomarkers
Pathologist (WEG), blinded with regard to study condi-
tion, will review clinical pathology reports and all slides
for each case; he then will choose one slide and one block
per case based on the presence of adequate tumor and the
histological grade of tumor on the slide will be representa-
tive of the entire tumor in the specimen. Slides will then
be prepared for determination of proliferation rate (Ki-67)
and other tumor markers (activated caspase 3, IR, AR,
VEGF, TNFβ, NFκB, 4E-BP1). Specific antibodies and dilu-
tions will be decided upon prior to analysis.Gut microbiome
At each time point, subjects collected fecal samples in
order to explore if changes in physical activity and diet-
ary intake affected the microbiome. Fecal samples were
collected after a bowel movement and using a sterile
wipe which was then placed in a plastic bag. Men were
asked to record the dates and times of collection. If sam-
ples were collected on days that preceded the scheduled
assessment, men were instructed to freeze the sample
and to submit it at the time of their appointment.
Microbiome analysis targeting the V4 region of the 16S
rRNA gene was performed using an Illumina MiSeq as
described previously [50]. File conversion and quality
control also were performed as documented earlier [51].
Analyses of the microbiome samples were performed
with the Quantitative Insight into Microbial Ecology
(QIIME) suite, version 1.7 [52] using a QIIME wrapper
called QWRAP as described previously [50, 51].
Statistical considerations and analyses
Sample size and statistical power
While this study was primarily undertaken as a feasibil-
ity pilot, initial power calculations were based on weight
loss data among men ages 50 years and older enrolled in
our UAB weight loss programs, who achieved a mean
(SD) weight loss of 12.4 (6.89) pounds over a 10-week
period. A sample size of 16/arm (which assumes 20 %
attrition) yields 98 % power to detect a difference in
means of 10.40 (i.e., Group 1 mean, μ1 of −12.40/Group
2 mean, μ2 of −2.00) assuming a similar SD for both
groups and using a 2-group, 2-sided t-test and α = .05.
Statistical comparison
Differences between the control and experimental
groups at baseline were assessed by t-tests for continu-
ous variables, and Fisher’s exact tests or Chi-square tests
for categorical variables. Median baseline PSA levels
were compared using the Wilcoxon test. Changes in an-
thropometric measures will be computed as follow-up
values - baseline values. The changes will be compared
between the treatment arms using a generalized linear
model with the change score as the dependent variable
and the treatment group as a predictor, controlling for
baseline measures. A similar model will be used for the
nutrition parameters assessed by the ASA 24 [47]. The
serum biomarker values that are not normally distrib-
uted will be log transformed prior to analyses. The
changes from baseline to follow-up will be computed on
the log-transformed data and will be compared by treat-
ment group with linear models controlling for baseline
values. Associations between tumor biomarkers and
adiposity measures will be examined with Pearson’s cor-
relations coefficients and linear regression. For bioener-
getic assessments, each blood sample will be analyzed
101 Men with Biopsy-proven Prostate Cancer Referred to Study
97 Men Screened




• 5 orthopedic exclusions
• 5 elected other treatment
• 3 surgery moved up
• 3 normal weight
• 1 cardiac exclusion
• 1 other cancer
• 1 prior treatment
Experimental (Weight Loss) Intervention
(n=20)






2 Cancelled Prostatectomy2 Cancelled Prostatectomy
1 Diagnosed with Metastatic Disease
1 Withdrew Consent
Fig. 3 CONSORT diagram






Age (years) – mean (SD) 59.9 (6.5) 61.9 (6.5) 0.13
BMI – mean (SD) 31.6 (4.4) 31.2 (4.7) 0.69
Study mentioned by physician – N (%)
Yes 21 (52.5) 31 (50.8) 0.87
No 19 (47.5) 30 (49.2)
Race– N (%)
African American 12 (30.0) 15 (24.6) 0.78
White 28 (70.0) 45 (73.8)
Other – 1 (1.6)
Miles from study site – N (%)
< 50 21 (53.8) 20 (35.7) 0.08
≥ 50 18 (46.2) 36 (64.3)
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means ± standard errors. Statistical significance will be
determined using either student’s T-tests or one-way
ANOVAs, followed by Tukey’s post hoc analyses with
p < 0.05 to designate statistical significance. Given the
pilot nature of this study, no adjustments will be
made for multiple comparisons.
Results
Accrual
This trial achieved all of its feasibility endpoints. Accrual
was met within a 2-year period, and required the screen-
ing of 101 patients in order to enroll 40 participants (an
enrollment rate of 39.6 %) (see Fig. 3 for CONSORT
diagram). Given physician turnover within our center, it
was necessary to partner with another institution in
order to meet our target. In analyses aimed at determin-
ing differences between enrollees vs. non-enrollees, we
found no differences with regard to age, race, BMI, and
whether or not the patient recalled that their urologist
mentioned the trial (Table 2). A non-significant trend
was noted with regard to distance from the study site.
Leading reasons for non-participation were “too busy”
(30 %), medical exclusions (21 %), distance (16 %)
and changes in plans surrounding surgery, i.e., opting
for a procedure at a different site, rescheduling at an
earlier date, and indecision or deciding on other
forms of treatment (11 %). Eighteen percent of non-
participants either expressed no reason or were un-
able to be contacted.Retention
Retention exceeded the benchmark of 80 % with 34 of
the 40 participants (85 %) completing the trial. Of those
who dropped-out, two-thirds did so because they de-
cided against surgery. There were no differences be-
tween completers vs. non-completers on age, race, BMI,
or Gleason score.
Adherence
Once enrolled, participants exceeded the previously set
benchmark for adherence, i.e., 95 %(9) as compared to
Demark-Wahnefried et al. BMC Cancer  (2016) 16:61 Page 10 of 12the 70 %. However, as previously stated, the intervention
was redesigned to accommodate home delivery through
the provision of heart rate monitors, scales and tele-
phone counseling.
Safety
No adverse events were observed or reported during the
intervention.
Discussion
Only two other weight loss interventions have been pur-
sued in the presurgical cancer setting, and neither of
these small studies (n = 8 and n = 19 [of which only half
were pre-surgical cases]), [19, 20] assessed effects on
tumor tissue. Therefore, this trial will be the first to as-
sess the impact of an acute period of negative energy
balance directly on the biology of the tumor, as well as
within the more global host environment. Given the
growing interest in weight control as a complementary
therapy to standard cancer treatment [1], such trials can
provide the mechanistic evidence needed to justify the
incorporation of diet and physical activity into oncologic
practice. As such, the methods listed herein can offer a
helpful framework for the design of future trials, as well
as data on feasibility that can be used to specifically
inform recruitment, retention, and the design of presur-
gical interventions.
Given the need to collect surgical specimens, presurgi-
cal trials dictate collaboration with co-investigators and
cancer centers that perform substantial numbers of pro-
cedures annually. Physician turnover and changes in
practice can cause unforeseen delays and in fact, oc-
curred with this trial. Therefore, partnerships with other
institutions are necessary and were instrumental in
achieving targeted accrual within the two-year timeframe
of this study. Nevertheless, patient indecision regarding
surgical treatment and its timing pose substantial bar-
riers to both recruitment and retention. Patients are un-
willing to delay their surgery and it was clear that if we
were to meet our accrual target, we needed to reduce
our initial 10-week intervention period to a shorter
period of time. As stated, 3-weeks was selected based on
the results of our previous trial [21]. Other issues related
to presurgical studies are the possibilities that surgeries
can be rescheduled and patients can decide to receive
their treatment elsewhere or not at all. Therefore, an ad-
equate margin of over accrual is necessary to ultimately
meet sample sizes that afford adequate power.
Our enrollment rate of almost 40 % was relatively
good for a diet and exercise intervention trial among
cancer survivors where reported rates of participation
have ranged from 6 % to 42 % [53]. The modifications
made to shorten the study period, as well as to de-
liver the intervention primarily through a home-basedapproach that relied on telephone counseling and
technologic support likely enhanced our participation.
Other criteria, such as those set to assure safety are
not as amenable to change and the fact that we did
not observe any serious adverse events provides fur-
ther support to the medical exclusions that were
made. However, given that distance and travel still
were listed as one of the top reasons for refusal, it
might be possible to overcome these barriers through
an added participant incentive or a higher reimburse-
ment rate for travel. Fifteen dollars was all the
current grant could afford and may have been too
low a stipend especially if the distance between the
patient’s home and the study site is substantial.
Finally, both retention and adherence exceeded the
benchmarks established for this trial. Moreover, with the
exception of only two men who were dissatisfied with
their randomization status, there was solid rapport be-
tween the study staff and participants.
Conclusion
This presurgical feasibility trial met all benchmarks
related to accrual, retention, adherence, and safety. As
analyses are completed, the potential impact of the
weight loss intervention on these biologic outcomes can
be determined and subsequently reported. Until then,
these methods have many applications that go far be-
yond the scope of this investigation.
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